| CAS NO: | 778576-62-8 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| Cas No. | 778576-62-8 |
| 别名 | N-(3,5-二氯吡啶-4-基)-4-二氟甲氧基-8-[(甲磺酰基)氨基]二苯并[B,D]呋喃-1-甲酰胺,GRC 3886 |
| Canonical SMILES | O=C(C1=C2C(OC3=CC=C(NS(=O)(C)=O)C=C23)=C(OC(F)F)C=C1)NC4=C(Cl)C=NC=C4Cl |
| 分子式 | C20H13Cl2F2N3O5S |
| 分子量 | 516.3 |
| 溶解度 | DMSO: 4 mg/mL (7.75 mM); Water:< 0.1 mg/mL (insoluble) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.IC50 value:Target: PDE4 [1]. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking• Br J Pharmacol. 2008 Oct;155(3):288-90. [2]. Study of Oglemilast for the Prevention of Asthma. [3]. Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD) [4]. Study of Oglemilast for the Treatment of Asthma |
m.cnreagent.com